Entera Bio (ENTX) Common Equity (2017 - 2026)

Entera Bio (ENTX) has reported Common Equity for 10 consecutive years, with $10.7 million the latest figure, recorded in Q1 2026.

• Quarterly Common Equity fell 44.85% year-over-year to $10.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.7 million (down 44.85% YoY) and the FY2025 annual result came in at $13.1 million, up 62.14% from the prior year.
• Common Equity fell to $10.7 million in Q1 2026 per ENTX's latest filing, from $13.1 million in the prior quarter.
• Over the last five years, Common Equity for ENTX reached as high as $19.7 million in Q1 2022 and fell as low as $6.2 million in Q3 2023.
• A 5-year average of $12.1 million and a median of $10.7 million in 2026 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2023 — Common Equity plunged 56.43% — and 2025, when it jumped 136.11%.
• Year by year, Common Equity stood at $11.8 million in 2022, then decreased by 11.64% to $10.4 million in 2023, then fell by 22.2% to $8.1 million in 2024, then soared by 62.14% to $13.1 million in 2025, then slipped by 18.43% to $10.7 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $10.7 million, $13.1 million, and $15.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.